Latest News Court Finds Bausch + Lomb Patent to Be Valid, Enforceable and Infringed By Staff Wednesday, January 18, 2017 12:27 AM BRIDGEWATER, N.J.—Bausch + Lomb, a global eye health company, said Tuesday it has won its patent infringement lawsuit with Vitamin Health Inc. in U.S. District Court and will receive, per the terms of the settlement, an undisclosed sum from Vitamin Health.According to court documents, a U.S. District Court for the Western District of New York issued a consent decree on Dec. 20, 2016, that found the Bausch + Lomb patents in dispute to be valid, enforceable and infringed. Vitamin Health acknowledged that the so-called “‘297 patent” is valid and enforceable and that certain other of Vitamin Health’s AREDS and AREDS 2 Formula eye vitamins infringe the ‘297 patent,” according to a Bausch + Lomb statement issued Jan. 17.The lawsuit was filed in September 2013, according to the court documents. Among other claims in the lawsuit, Bausch + Lomb accused Vitamin Health of infringing certain Bausch + Lomb’s U.S. patents covering PreserVision AREDS and AREDS 2 Formula eye vitamins through Vitamin Health’s manufacture and sale of certain of its Viteyes eye vitamins, according to the Bausch + Lomb statement. The parties reached a settlement on unresolved issues in mid-2016 less than two weeks after the trial had begun, according to the court documents.Joseph Gordon, senior vice president and general manager of the Bausch + Lomb Consumer Healthcare group, said, “As the leader in ocular nutrition, Bausch + Lomb is committed to providing the most current, science-based eye vitamin formulations. Therefore, when these or any of our products are infringed, we will vigorously defend our intellectual property and innovations to ensure our customers can continue to rely on products that are based on a robust body of scientific and clinical research.”